Subscribe To
AWKNF / Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
AWKNF News
By Proactive Investors
December 19, 2022
Awakn Life Sciences currently undervalued say Stifel analysts noting de-risked Phase 3 ketamine trial and clinic momentum
Awakn Life Sciences Corp (NEO:AWKN), a biotechnology company developing psychedelic therapies to treat addiction with a near-term focus on alcohol use more_horizontal
By Benzinga
April 4, 2022
Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock. Awakn is a publicly traded company which trades o more_horizontal